[go: up one dir, main page]

SI2185581T1 - Postopki in sestavki, uporabni v zdravljenju mukozitisa - Google Patents

Postopki in sestavki, uporabni v zdravljenju mukozitisa

Info

Publication number
SI2185581T1
SI2185581T1 SI200831541T SI200831541T SI2185581T1 SI 2185581 T1 SI2185581 T1 SI 2185581T1 SI 200831541 T SI200831541 T SI 200831541T SI 200831541 T SI200831541 T SI 200831541T SI 2185581 T1 SI2185581 T1 SI 2185581T1
Authority
SI
Slovenia
Prior art keywords
mucositis
treatment
methods
compositions useful
compositions
Prior art date
Application number
SI200831541T
Other languages
English (en)
Inventor
David Paul Hesson
Michael Scott Kramer
Original Assignee
Promedior, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior, Inc. filed Critical Promedior, Inc.
Priority claimed from EP08826168.0A external-priority patent/EP2185581B1/en
Publication of SI2185581T1 publication Critical patent/SI2185581T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4737—C-reactive protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
SI200831541T 2007-07-06 2008-07-07 Postopki in sestavki, uporabni v zdravljenju mukozitisa SI2185581T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95863407P 2007-07-06 2007-07-06
US96134307P 2007-07-20 2007-07-20
US12/215,700 US9884899B2 (en) 2007-07-06 2008-06-27 Methods for treating fibrosis using CRP antagonists
EP08826168.0A EP2185581B1 (en) 2007-07-06 2008-07-07 Methods and compositions useful in the treatment of mucositis
PCT/US2008/008340 WO2009009034A2 (en) 2007-07-06 2008-07-07 Methods and compositions useful in the treatment of mucositis

Publications (1)

Publication Number Publication Date
SI2185581T1 true SI2185581T1 (sl) 2016-01-29

Family

ID=40090306

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200831541T SI2185581T1 (sl) 2007-07-06 2008-07-07 Postopki in sestavki, uporabni v zdravljenju mukozitisa

Country Status (7)

Country Link
US (1) US9884899B2 (sl)
EP (1) EP2176287A2 (sl)
JP (2) JP2010532872A (sl)
AU (1) AU2008275678B9 (sl)
CA (1) CA2692637A1 (sl)
SI (1) SI2185581T1 (sl)
WO (1) WO2009009019A2 (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2340309A2 (en) * 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US20110256110A1 (en) * 2008-10-24 2011-10-20 Children's Hospital Los Angeles Amniotic fluid cells and uses thereof
CA2754961C (en) * 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
EP2405929B1 (en) * 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) * 2009-06-17 2015-11-24 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用
CA2794187C (en) * 2010-03-24 2020-07-14 Rxi Pharmaceuticals Corporation Rna interference in ocular indications
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
WO2011132085A2 (en) * 2010-04-21 2011-10-27 Kalluri, Raghu Methods and compositions for treating fibrosis
TWI497076B (zh) 2010-06-25 2015-08-21 Univ Nat Cheng Kung 適合體及ｃ－反應蛋白檢測方法
CN103403030A (zh) 2011-02-21 2013-11-20 菲布他丁有限合伙公司 治疗和诊断疾病的方法
EP2793927B1 (en) * 2011-12-21 2019-03-06 Promedior, Inc. Serum amyloid p-antibody fusion proteins
WO2013141816A1 (en) * 2012-03-21 2013-09-26 Singapore Health Services Pte Ltd A method of diagnosing and/or treating corneal fibrosis
CN105792831A (zh) * 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
JP6836987B2 (ja) 2014-09-05 2021-03-03 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． Ｔｙｒまたはｍｍｐ１を標的とする核酸を用いて老化および皮膚障害を処置するための方法
JP6835430B2 (ja) * 2015-03-02 2021-02-24 ジェイティー インターナショナル エス．エイ．ＪＴ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． マグネット式閉鎖機構を備えるパッケージ
WO2017018385A1 (ja) * 2015-07-24 2017-02-02 公立大学法人名古屋市立大学 骨髄線維症の状態の診断を補助する方法、予後の予測を補助する方法、及び治療効果のモニター方法、並びにそれらの方法に用いるマーカー及び装置
JP2018529756A (ja) * 2015-07-31 2018-10-11 メディミューン リミテッド ヘプシジン媒介性障害を治療するための方法
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
MA51584A (fr) 2018-01-05 2020-11-11 Corvidia Therapeutics Inc Méthodes de traitement d'une inflammation médiée par il-6 sans immunosuppression
CN112839708A (zh) * 2018-06-20 2021-05-25 胺细拉健康公司 用于减少或治疗纤维化的组合物和方法
EP3911673A1 (en) * 2019-01-16 2021-11-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of agents capable of inducing lc3-associated phagocytosis for treating sustained inflammation in patients suffering from chronic liver disease
WO2021252344A2 (en) * 2020-06-09 2021-12-16 The Texas A&M University System Therapeutics for treatment of covid-19 symptoms
CN115154606B (zh) * 2022-06-20 2023-10-20 中国医学科学院基础医学研究所 FcγRⅢ抑制剂作为靶点在制备治疗肺纤维化药物中的应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1562244A (en) * 1976-11-11 1980-03-05 Lock P M Wound dressing materials
GB1594389A (en) * 1977-06-03 1981-07-30 Max Planck Gesellschaft Dressing material for wounds
GB8516081D0 (en) * 1985-06-25 1985-07-31 Ciba Geigy Ag Assay & purification of amyloid components
US6071517A (en) * 1986-07-07 2000-06-06 Medarex, Inc. Bispecific heteroantibodies with dual effector functions
DE3880647T2 (de) * 1987-11-20 1993-11-18 Kanegafuchi Chemical Ind Sorbentmittel für Serum-Amyloid-Proteine.
US7070994B2 (en) * 1988-03-21 2006-07-04 Oxford Biomedica (Uk) Ltd. Packaging cells
US5272258A (en) * 1989-06-29 1993-12-21 Rush-Presbyterian-St. Luke's Medical Center Monoclonal antibodies to C-reactive protein
US5092876A (en) * 1989-08-30 1992-03-03 The United States Of America As Represented By The Department Of Health And Human Services Cell attachment peptides derived from amyloid P component
WO1992021364A1 (en) 1991-05-31 1992-12-10 New England Deaconess Hospital Corporation Cea-binding proteins and methods for their isolation and use
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
US5654186A (en) * 1993-02-26 1997-08-05 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US5804446A (en) * 1993-02-26 1998-09-08 The Picower Institute For Medical Research Blood-borne mesenchymal cells
US6054121A (en) * 1993-02-26 2000-04-25 The Picower Institute For Medical Research Modulation of immune responses in blood-borne mesenchymal cells
AU7043694A (en) 1993-05-27 1994-12-20 Regents Of The University Of Michigan, The Method of treatment and prevention of immune complex-induced lung injury
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
US5981470A (en) 1994-06-07 1999-11-09 The University Of Birmingham Uterine fibroid treatment
US5989811A (en) * 1994-09-29 1999-11-23 Urocor, Inc. Sextant core biopsy predictive mechanism for non-organ confined disease status
US5750345A (en) 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
AU712819B2 (en) * 1996-01-25 1999-11-18 Profylakse Aps Pharmaceutical composition comprising serum amyloid P component for proph ylactic or therapeutic treatment of virus infections and a kit for detecting binding of compositions to virus components
US6365570B1 (en) * 1997-10-10 2002-04-02 Universiteit Utrecht Pharmaceutical and diagnostic use of Serum Amyloid P component
KR20010041010A (ko) 1998-02-17 2001-05-15 메다렉스, 인코포레이티드 Ｆｃ 수용체 리간드를 사용하여 마크로파지 매개 질환을치료하고 진단하는 방법
ES2220257T1 (es) 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.
JPH11319542A (ja) 1998-05-08 1999-11-24 Tokuyama Corp 超薄層の製造方法
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6600019B2 (en) * 2000-01-06 2003-07-29 Curagen Corporation Polypeptides and nucleic acids encoding same
EP1267795A1 (en) 2000-03-30 2003-01-02 Brennen Medical Inc. Anti-microbial and immunostimulating composition
US20040068095A1 (en) * 2001-03-14 2004-04-08 Shimkets Richard A. Novel human proteins, polynucleotides encoding them and methods of using the same
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US6872541B2 (en) * 2001-07-25 2005-03-29 Coulter International Corp. Method and compositions for analysis of pentraxin receptors as indicators of disease
US6537811B1 (en) * 2001-08-01 2003-03-25 Isis Pharmaceuticals, Inc. Antisense inhibition of SAP-1 expression
US20030199442A1 (en) 2001-10-09 2003-10-23 Alsobrook John P. Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US7022476B2 (en) * 2002-02-26 2006-04-04 New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof
GB0211136D0 (en) 2002-05-15 2002-06-26 Univ London Treatment and prevention of tissue damage
RU2316318C2 (ru) * 2002-05-17 2008-02-10 Новартис Аг Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
WO2004016750A2 (en) 2002-08-14 2004-02-26 Macrogenics, Inc. FcϜRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7763256B2 (en) * 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
CA2509241C (en) * 2002-12-23 2013-07-30 William Marsh Rice University Use of serum amyloid p (sap) and related compositions for the suppression of fibrosis-related diseases
US8012472B2 (en) * 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
AU2003302340B8 (en) 2002-12-24 2008-09-11 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US20070149450A1 (en) 2003-02-27 2007-06-28 Ranjit Bhardwaj Method for reducing levels of c-reactive protein
MXPA06011796A (es) 2004-04-16 2007-05-07 Macrogenics Inc Anticuerpos especificos de fc(riib y metodos para el uso de los mismos.
AU2005244058B2 (en) 2004-05-10 2011-07-28 Macrogenics, Inc. Humanized FcgammaRIIB specific antibodies and methods of use thereof
JP2008508860A (ja) 2004-06-03 2008-03-27 メダレツクス・インコーポレーテツド Ｆｃγ受容体１（ＣＤ６４）に対するヒトモノクローナル抗体
WO2006002930A2 (en) 2004-06-30 2006-01-12 Friedrich-Alexander- Universitaet Erlangen- Nuernberg FcϜRIIa POLYMORPHISM AND ITS USE IN DIAGNOSIS
US20080038192A1 (en) * 2004-07-19 2008-02-14 Neurochem Inc. Diagnostic Methods Of Multiple Organ Amyloidosis
CA2577405A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Anti-fc-gamma riib receptor antibody and uses therefor
JP2008513027A (ja) * 2004-09-17 2008-05-01 バイオマリン ファーマシューティカル インコーポレイテッド フェニルアラニンアンモニアーリアーゼの改変体および化学的に修飾された改変体
JP2008516586A (ja) 2004-09-30 2008-05-22 メダレックス インコーポレーティッド Ｆｃγ受容体ＩＩ（ＣＤ３２）に対するヒトモノクローナル抗体
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
EP1938104A2 (en) 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
LT2029173T (lt) 2006-06-26 2016-11-10 Macrogenics, Inc. Fc riib specifiniai antikūnai ir jų panaudojimo būdai
EP2094289B1 (en) * 2006-12-04 2013-03-13 Promedior, Inc. Combination of sap and enalapril for use in the treatment of fibrotic or fibroproliferative disorders
DK2185581T3 (en) 2007-07-06 2015-12-14 Promedior Inc Methods and compositions suitable for treating mucositis
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
EP2405929B1 (en) * 2009-03-11 2018-06-06 Promedior Inc. A sap polypeptide for use in the treatment of autoimmune disorders and graft vs host disease
CA2754961C (en) 2009-03-11 2018-04-10 Promedior, Inc. Treatment and diagnostic methods for hypersensitive disorders
EP2413903A4 (en) 2009-04-01 2013-01-02 Promedior Inc PULMONARY AND NASAL ADMINISTRATION OF AMYLOID P SERUM SUBSTANCE
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
JP5822826B2 (ja) * 2009-06-17 2015-11-24 プロメディオール， インコーポレイテッド Ｓａｐ変異体及びその使用

Also Published As

Publication number Publication date
WO2009009019A2 (en) 2009-01-15
JP2016001196A (ja) 2016-01-07
AU2008275678B9 (en) 2014-11-27
EP2176287A2 (en) 2010-04-21
WO2009009019A3 (en) 2009-04-23
AU2008275678A1 (en) 2009-01-15
US9884899B2 (en) 2018-02-06
JP2010532872A (ja) 2010-10-14
CA2692637A1 (en) 2009-01-15
AU2008275678B2 (en) 2014-06-26
US20090202520A1 (en) 2009-08-13

Similar Documents

Publication Publication Date Title
SI2185581T1 (sl) Postopki in sestavki, uporabni v zdravljenju mukozitisa
ZA200900388B (en) Compositions and methods for the treatment of mucositis
HRP20160902T1 (hr) Pripravci i postupci uporabe forbolskih estera
ZA201001300B (en) Antigen-asjuvant compositions and methods
HK1105975A1 (en) Indoles useful in the treatment of inflammation
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
PT2185581E (pt) Processos e composições úteis no tratamento de mucosite
EP2079526A4 (en) COMPOSITIONS AND ITS USES IN THE TREATMENT OF WOUNDS
ZA201001473B (en) Compositions and methods for the modification of physiological responses in plants
EP2170404A4 (en) COMPOSITIONS WITH HUMAN EGFR SIRNA AND METHOD OF USE
ZA201001616B (en) Cleaning and/or treatment compositions
EP2282648A4 (en) PREBIOTIC COMPOSITIONS AND MANUFACTURING AND USE METHOD THEREFOR
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
IL211204A0 (en) Mucoadherents compositions and their use
GB0721291D0 (en) Methods and compositions
EP2249789A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF XEROSOMY
IL190969A0 (en) Pyrazoles useful in the treatment of inflammation
EP1937075A4 (en) SYNERGIC COMPOSITION AND METHOD OF USE
GB0719526D0 (en) Compositions and methods
ZA201004894B (en) Nuctraceutical composition and methods of use
PL2250179T3 (pl) Kompozycja na bazie lecytyny i jej zastosowanie w żywności
ZA201004893B (en) Nuctraceutical composition and methods of use
GB0714500D0 (en) composition and treatment
GB2461611B (en) Composition and use thereof
GB0504657D0 (en) Compositions and methods of treatment